Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group.

Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v. over 60 min without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulkes, A., Smyth, J., Sessa, C., Dirix, L. Y., Vermorken, J. B., Kaye, S., Wanders, J., Franklin, H., LeBail, N., Verweij, J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1994
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2033505/
https://www.ncbi.nlm.nih.gov/pubmed/7914428

Ejemplares similares

Ejemplares similares